PUBLISHER: The Business Research Company | PRODUCT CODE: 1939328
PUBLISHER: The Business Research Company | PRODUCT CODE: 1939328
Bifurcation lesions in the context of coronary arteries refer to constrictions that occur adjacent to or involve the origin of a critical side branch that one aims to preserve. This situation arises when there is an accumulation of plaque deposits, causing the artery to become too narrow, thereby hindering adequate blood flow to the heart.
The main categorizations of bifurcation lesions are one-stent and two-stent approaches. In a one-stent bifurcation lesion procedure, the side branch is provisionally stented if intervention is deemed necessary based on clinical complaints, angiographic results, or other relevant factors. In this approach, the main branch is stented first. The bifurcation angle is determined by the internal angle between the main and side branches. These types of bifurcation lesions are encountered in both coronary and peripheral vascular contexts.
Tariffs are impacting the bifurcation lesions market by increasing costs of imported stents, guidewires, imaging catheters, and interventional cardiology devices. Cardiac centers in North America and Europe are most affected due to reliance on imported high-precision medical devices, while Asia-Pacific faces higher manufacturing and export costs. These tariffs are increasing procedure costs and inventory expenses. However, they are also supporting regional device manufacturing and encouraging innovation in cost-effective coronary intervention technologies.
The bifurcation lesions market research report is one of a series of new reports from The Business Research Company that provides bifurcation lesions market statistics, including bifurcation lesions industry global market size, regional shares, competitors with a bifurcation lesions market share, detailed bifurcation lesions market segments, market trends and opportunities, and any further data you may need to thrive in the bifurcation lesions industry. This bifurcation lesions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The bifurcation lesions market size has grown strongly in recent years. It will grow from $2.84 billion in 2025 to $3.1 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to increasing prevalence of coronary artery disease, growth in interventional cardiology procedures, adoption of stenting over surgical bypass, availability of specialized bifurcation stents, rising clinical expertise in complex interventions.
The bifurcation lesions market size is expected to see strong growth in the next few years. It will grow to $4.34 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing use of precision-guided coronary interventions, rising demand for next-generation stent technologies, expansion of personalized cardiovascular treatments, growing integration of imaging and analytics, increasing focus on procedural success rates. Major trends in the forecast period include increasing adoption of advanced stent techniques for complex lesions, rising use of imaging-guided bifurcation interventions, growing preference for drug-eluting stents, expansion of minimally invasive coronary procedures, enhanced focus on long-term vessel patency.
The rising healthcare expenditure is expected to drive the growth of the bifurcation lesions market in the future. Healthcare infrastructure encompasses all expenses related to medical care, preventive measures, public health initiatives, rehabilitation, community health activities, and health research. Increased healthcare spending enables healthcare facilities to invest in cutting-edge equipment and technologies, including advanced interventional cardiology devices for treating bifurcation lesions. For example, in November 2023, the Canadian Institute for Health Information, a non-profit organization based in Canada, projected that total health spending in Canada would increase by 2.8% in 2023, following a modest growth of only 1.5% in 2022. Consequently, the rising healthcare expenditure is propelling the growth of the bifurcation lesions market.
Leading companies in the bifurcation lesions market are actively developing innovative products such as drug-eluting coronary stent systems to expand their customer base, increase sales, and drive revenue growth. A drug-eluting coronary stent system is a specialized medical device used in interventional cardiology for the treatment of coronary artery disease. In August 2023, Medtronic PLC, an Ireland-based medical device company, introduced the Onyx Frontier drug-eluting stent (DES) to address non-left main bifurcation lesions using the provisional stenting technique. This product incorporates several design enhancements, including a dual-layer balloon, reduced crossing profile, and enhanced catheter flexibility. The improvements result in a 16% enhancement in deliverability compared to the prior-generation Resolute Onyx DES, maintaining the same level of radial strength. Onyx Frontier offers an extensive range of sizes, accommodating patient needs with diameters ranging from 2.0mm to 5.0mm, with specific sizing for the treatment of extra-large vessels, including those in the left main. The product inherits clinical data and indications from Resolute Onyx, including approval for treating bifurcation lesions, left main percutaneous coronary intervention (PCI), and a recommended one-month duration of dual antiplatelet therapy (DAPT) for high bleeding risk patients.
In June 2024, Boston Scientific Corporation, a medical technology company based in the US, acquired Silk Road Medical, Inc. for $1.18 billion. The acquisition aims to enhance Boston Scientific's product offerings and competitive position in the vascular market by leveraging innovative technologies to improve patient outcomes and expand into new markets. Silk Road Medical, Inc. is a medical device firm that focuses on developing innovative solutions for carotid artery procedures.
Major companies operating in the bifurcation lesions market are Boston Scientific Corporation, Terumo Medical Corporation, Spectranetics Corporation, Medtronic plc, Abbott Laboratories, Biosensors International Group Ltd., B. Braun Melsungen AG, Cook Medical LLC, Cordis Corporation, InspireMD Inc., MicroPort Scientific Corporation, OrbusNeich Medical Company Limited, Biotronik SE & Co. KG, Medinol Ltd., Meril Life Sciences Pvt. Ltd., Sahajanand Medical Technologies Pvt. Ltd., Elixir Medical Corporation, Veryan Medical Ltd., Zorion Medical Inc., Svelte Medical Systems Inc., Amaranth Medical Inc., Cardiva Medical Inc.
North America was the largest region in the bifurcation lesions market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bifurcation lesions market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the bifurcation lesions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The bifurcation lesions market includes revenues earned by proximal main branch (MB), distal MB and side branch (SB). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Bifurcation Lesions Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses bifurcation lesions market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for bifurcation lesions ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bifurcation lesions market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.